Urologist, Professor, Departments of Surgery and Oncology, University of Alberta, Alberta Heritage Foundation for Medical Research Senior Scholar, University of Alberta, Edmonton, AB
Dr. Moore completed his MD at the University of Alberta in 1986, after which he pursued his PhD in 1991 in experimental surgery and radiobiology. He completed a residency in urology in 1993. Dr. Moore’s research interests focus on novel modalities/therapeutics for treating bladder and prostate cancer, and means of improving survival of transplanted organs. This includes laser surgery (including PDT), development of laser and light delivery/detection equipment, drug development, drug testing, drug delivery, biochemical and biological modifiers, molecular markers, predictive assays and gene therapy.
Shi W, Paproski RJ, Moore R, Zemp R. Detection of circulating tumor cells using targeted surface-enhanced Raman scattering nanoparticles and magnetic enrichment. J Biomed Opt. 2014 May;19(5):056014.
Yoo SS, Razzak R, Bédard E, Guo L, Shaw AR, Moore RB, Roa WH.Layered gadolinium-based nanoparticle as a novel delivery platform for microRNA therapeutics. Nanotechnology. 2014 Oct 24;25(42):425102.
Wood L, Bjarnason GA, Black PC, Cagiannos I, Heng DY, Kapoor A, Kollmannsberger CK, Mohammadzadeh F, Moore RB, Rendon RA, Soulieres D, Tanguay S, Venner P, Jewett M, Finelli A. Using the Delphi technique to improve clinical outcomes through the development of quality indicators in renal cell carcinoma. J Oncol Pract. 2013 Sep;9(5):e262-7.
Xiao Z, Mak A, Koch K, Moore RB. A molecular complex of bovine milk protein and oleic acid selectively kills cancer cells in vitro and inhibits tumour growth in an orthotopic rat bladder tumour model.BJU Int. 2013 Jul;112(2):E201-10.
Potts KG, Hitt MM, Moore RB. Oncolytic viruses in the treatment of bladder cancer. Adv Urol. 2012;2012:404581.
Xiao Z, Hanel E, Mak A, Moore RB. Antitumor Efficacy of Intravesical BCG, Gemcitabine, Interferon-α and Interleukin-2 as Mono- or Combination-Therapy for Bladder Cancer in an Orthotopic Tumor Model. Clin Med Insights Oncol. 2011;5:315-23.
Moibi JA, Mak AL, Sun B, Moore RB. Urothelial cancer cell response to combination therapy of gemcitabine and TRAIL. Int J Oncol. 2011 Jul;39(1):61-71.
Xiao Z, Owen RJ, Liu W, Tulip J, Brown K, Woo T, Moore RB. Lipophilic photosensitizer administration via the prostate arteries for photodynamic therapy of the canine prostate. Photodiagnosis Photodyn Ther. 2010 Jun;7(2):106-14.
Sun B, Moibi JA, Mak A, Xiao Z, Roa W, Moore RB. Response of bladder carcinoma cells to TRAIL and antisense oligonucleotide, Bcl-2 or clusterin treatments. J Urol. 2009 Mar;181(3):1361-71.